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Abstract
An important goal in cancer chemotherapy is to sensi-
tively and quantitatively monitor the response of indi-
vidual patients’ tumors to successful, or unsuccessful,
therapy so that regimens can be altered iteratively.
Currently, tumor response is monitored by frank
changes in tumor morphology, yet these markers take
long to manifest and are not quantitative. Recent stud-
ies suggest that the apparent diffusion coefficient of
( )water ADC , measured noninvasively with magneticw
resonance imaging, is sensitively and reliably in-
creased in response to successful CTx. In the present
study, we investigate the combination chemotherapy
response of human breast cancer tumor xenografts
sensitive or resistant to Paclitaxel by monitoring
changes in the ADC . Our results indicate that there isw
a clear, substantial, and early increase in the ADCw
after successful therapy in drug sensitive tumors and
that there is no change in the ADC in p-glycoprotein–w
positive tumors, which are resistant to Paclitaxel. The
mechanism underlying these changes is unknown yet
is consistent with apoptotic cell shrinkage and a con-
comitant increase in the extracellular water fraction.
Introduction
Breast cancer is the second leading cause of death, after
lung cancer, in American women. Paclitaxel, an inhibitor of
microtubule depolymerization, is an effective chemothera-
peutic agent in the adjuvant treatment of breast cancer, with
a response rate ranging from 32% to 56% alone, or from
( )44% to 100% in combination chemotherapy CTx with
[ ]anthracyclines 1 . An important goal in cancer CTx is to
tailor treatment regimens to individual patients’ genotype,
tumor type, and physiology. In order to accomplish this, it
will be essential to sensitively and quantitatively monitor the
response of individual patients’ tumors to successful, or
unsuccessful, therapy so that regimens can be altered
adaptively. Currently, tumor response is monitored by frank
changes in tumor morphology, such as the size or margins
of the tumor. However, these macroscopic markers take
long to manifest and typically are not quantitative or quanti-
fied with modest precision. An intriguing potential improve-
ment in therapeutic monitoring is the noninvasive measure-
( )ment of the apparent diffusion coefficient of water ADCw
( )by magnetic resonance imaging MRI . Recent studies have
( )shown that diffusion-weighted MRI DWI can detect tumor
[ ]response to CTx sensitively, quantitatively, and early 2–5 .
In the present study, we investigate the CTx response of
drug-sensitive and drug-resistant human tumor xenografts
to Paclitaxel by monitoring changes in the ADC by DWI.w
Paclitaxel is a microtubule depolymerization inhibitor
commonly used in CTx. It was chosen because it is an
extremely potent drug against tumors from MCF7/S cells.
Its clinical antitumor activity has been demonstrated in pa-
tients with malignancies such as carcinoma of the ovaries,
breast, lung, bladder, testes, esophagus, and endometrium
[ ]6 . It has also been shown to be more modestly active
against Kaposi’s sarcoma, lymphoma, and carcinoma of the
[ ]cervix and stomach 6 . In contrast, taxanes do not have
significant activity against neoplasms derived from tissues
( )that overexpress p-glycoprotein P-gp , including human
[ ]breast tumor cells 7,8 .
DWI is an early, noninvasive indicator of ischemic insult
and can be used to successfully diagnose the extent of
injury and the response to therapy in a variety of nontumor
[ ]systems such as brain 9–11 . To date, it has been used
primarily in neurological MRI examinations. The physio-
logical mechanisms underlining the ADC changes in thesew
systems are thought to involve a shift of water between
extracellular and intracellular compartments that accompa-
nies cell swelling or shrinkage. Recently published models
have provided a theoretical framework wherein ischemic-as-
[ ]sociated changes in ADC can be interpreted 12,13 . In thew
case of stroke, decreases in ADC values are consistentw
with cell swelling, causing a shift of water from the extracel-
[ ]lular to the intracellular space 14,15 . In the case of rapid
hemodialysis of nephrectomized rats, the observed in-
creases of ADC are consistent with hypernatremia-in-w
duced cell shrinkage and concomitant accumulation of wa-
[ ]ter in the extracellular space 16 . The measurement of
ADC has not been extensively applied to the study ofw
cancer CTx. However, in the few extant studies, the results
are extremely promising.
The use of DWI to monitor the response of tumors to CTx
[ ]was first proposed by Ross and Chenevert 2,17 . Subse-
[ ] 1quently, Evelhoch’s group 4,5 used H MRS to measure
the ADC in sarcoma xenografts to detect an early re-w
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( ) ( )sponse to cyclophosphamide Cp and 5-fluorouracil 5FU .
In the case of Cp, ADC was measured before commence-w
ment of CTx and up to 9 days after treatment. Tumor ADCw
increased significantly within 2 days of treatment, which was
prior to any observable change in tumor volume or other
MRI visible changes. Results with 5FU were similar. Cp is a
DNA alkylating agent and 5FU is an antimetabolite. In the
present study, we use Paclitaxel, which acts via a distinct
mechanism, to test the hypothesis that changes in ADCw
are a general response to successful CTx. In addition, our
study measured the ADC by DWI, as compared tow
whole-tumor measurements. The advantage of using DWI is
that spatial distribution of the ADC in the tumor is ob-w
tained. Thus, the responsiveness of various parts in the
tumor to CTx can be analyzed.
Materials and Methods
Cell Lines and Tumors
(In the current study Paclitaxel MeadJohnson, Princeton,
)NJ was used as CTx agent against tumors grown in severe
( )combined immunodeficient SCID mice from MCF7/S and
MCF7/D40 cell lines. MCF7/S cells are parental, drug
sensitive, breast carcinoma cells that were originally ob-
(tained from American Type Culture Collection ATCC
)aHTB-22, Rockville, MD . MCF7/D40 were generated in
vitro by successive culturing in increasing concentrations of
( )doxorubicin. These cells are P-gp positive and are 40-fold
resistant to doxorubicin, compared to MCF7/S. The CTx
responses of these cells to a variety of drugs have been
[ ]demonstrated in vitro and in vivo 18 .
SCID mice were obtained from the SCID mouse core
facility at the University of Arizona Comprehensive Cancer
Center. Tumors were grown by implanting 5=106 cells
( )in Matrigel Collaborative Research, Bedford, MA into
the mouse flanks. After 4 to 5 days, tumors reached a
( 3)size 200–400 mm appropriate for MRI analyses. Pacli-
taxel-treated animals were injected intraperitoneally with a
( )single dose 27 mg/kg immediately after the first MRI
(experiment and given subsequent booster injections 18
)mg/kg every other day. Control mice were injected an
equivalent volume of a 0.9% saline solution.
SCID mice are a good system with which to examine the
effects of chemotherapeutic agents on human tumor
[ ]xenografts 19 . Melanoma, colon carcinoma, lung carci-
noma, leukemia, prostate, and breast cell lines have all
been successfully grown to tumors in SCID mice and suc-
( )cessfully treated with CTx, e.g., tamoxifen breast ; Pacli-
( ) ( ) ( )taxel breast ; Cp breast, leukemia ; carmustine colon ,
( ) ( )cisplatin colon ; and doxorubicin leukemia . Therapeutic
responses have been determined from tumor volumes,
measured with calipers and calculated according to the
( 2) [ ]formula length=width /2 20 .
Measurement of ADCw
MRI was done on a 40 cm clear bore Bruker Biospec 4.7
( 1 ) (Tesla 200 MHz H imaging spectrometer Bruker, Karls-
)ruhe, Germany . In all cases, animals were anesthetized
with ketamine:acepromazine:xylazine at 72:6:6 mg/kg, and
tumors were placed within a 1 cm diameter, 2-turn solenoidal
coil. In DWI, the sample is pulsed with a strong magnetic
field gradient, which imparts spatially dependent phase shifts
( )on individual spins e.g., water protons . After an evolution
time, a refocusing pulse is imposed such that stationary
( )spins i.e., those with low diffusion coefficient, ADC willw
completely refocus, whereas spins that have moved during
( )the evolution time i.e., those with high ADC will notw
refocus, leading to signal attenuation. In DWI, the magni-
tude of signal is reduced by increasing the gradient strength
( )or the evolution time Eq. 1 . The parameters of gradient
strength and evolution time are combined in the b-factor.
DWI were obtained by using a diffusion-weighted stimulated
[ ]echo pulse sequence 21 at 3 different b values. Other
imaging parameters included TE, 10 ms; TR, 500 ms;
diffusion time D, 50 ms; diffusion-weighting gradients dura-
)tion d, 4 ms; FOV 2.5 cm, matrix size 128=128 .
( )DWI were then fit on a pixel-by-pixel basis to Eq. 1 by
using a routine written for this purpose in interactive data
( ) ( )language IDL . Eq. 1 relates the decrease in signal inten-
sity observed with increasing b-factor or ADC :w
SsS eyb ŽADC . 1Ž .0
with
bsg 2G2d 2 Dydr3Ž .
where S and S are the signal intensities in each pixel with0
and without diffusion weighting, respectively; d is the diffu-
sion-weighting pulse duration; D the delay between the start
of the diffusion-weighting pulse; g the gyromagnetic ratio;
and G the gradient strength. In the calculation of b values,
cross terms between diffusion-weighting gradients and
imaging gradients were taken into account. A possible
source of error is the potential anisotropic nature of tumor
tissue. In the presence of anisotropy the measured ADCw
Figure 1. Tumor volume–based response indexes to Paclitaxel for
MCF7/S and MCF7/D40 tumors. In these experiments, the response
indexes for the MCF7/D40 and MCF7/S tumors were calculated over a
7 -day treatment regime.
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Figure 2. DWI obtained from a 12 -day - old tumor at different values of
the diffusion-weighting factor, b. A. bs 0.027=10 9 s/m2, B. bs 0.249
=10 9 s/m2, C. bs 0.442=10 9 s/m2. D. ADC map calculated fromw
the images shown in A through C. Final ADC values were obtained byw
summing 3 ADC maps obtained with diffusion weighting in 3 orthogo-w
( )nal directions see Materials and Methods .
becomes a function of the orientation of the tumor relative to
the direction of the diffusion gradients. To overcome this
problem, we measured ADCs in 3 orthogonal directions and
calculated the trace of the ADC , a parameter independentw
[ ]of orientation 22 .
Results
Response of MCF-7 Tumors to Paclitaxel in Vivo
Figure 1 shows the responses of 8 MCF7/S and 8
MCF7/D40 tumors after treatment with Paclitaxel. Although
tumor growth was exponential, data were expressed as the
increase in tumor volumes by day 7, normalized to an
average per-day basis. As shown in this figure, untreated
tumors increase in volume at a rate of 115 to 140 mm3 per
day. In response to Paclitaxel, the drug-sensitive MCF7/S
tumors uniformly halted tumor growth, with average volume
gains near 5 mm3 per day, whereas the drug-resistant
tumors continued to grow, with volume gains greater than
105 mm3 per day. The growth rate of the drug-resistant
tumors was indistinguishable from the growth rate of un-
treated tumors. These data demonstrate that the SCID
mouse model is relevant to study the response of Paclitaxel
CTx in drug-sensitive and drug-resistant tumors grown from
MCF7/S and MCF7/D40 cell lines, respectively.
Measurements of ADC in MCF7 Tumorsw
DWI images at different b-factors are shown in Figure 2A
to C from a representative MCF7 tumor implanted in the
( )Figure 3. A,B Effect of Paclitaxel on the distribution of ADC values in MCF7 /S and MCF7 /D40 tumors compared to untreated tumors. ADCw valuesw
were obtained 48 hours after the beginning of CTx. To allow for a direct comparison, the number of pixels in each tumor was normalized to a value of
( ) ( )1000 and the data averaged for each group treated and control mice . C,D Effect of Paclitaxel on the growth of MCF7/S and MCF7/D40 tumors
compared to untreated tumors.
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flanks of a SCID mouse. Note that the image shown was
obtained 12 days after tumor inoculation to illustrate the
diffusion behavior of necrosis. As the b-factor is increased,
the pixel intensities inversely reflect the diffusion of the
(water molecules in the tumor i.e., the higher the diffusion,
)the more rapidly the signal intensity is attenuated . Thus,
(signals originating from the necrotic spaces dark regions
)within the tumor lose intensity faster than the surrounding
viable regions of the tumor. This is due to a higher diffusion
of water in these regions of the tumor with lower cellularity.
The ADC map shown in Figure 2D was generated byw
( )fitting the signal intensity of each pixel to Eq. 1 , as de-
scribed in Materials and Methods. The structural details
seen in Figure 2A to C are also observed in the ADC map.w
However, the ADC map is a quantitative representation ofw
absolute values wherein the higher D values are bright, and
the DWI in Figure 2A to C show only relative values, with
higher D values being dark due to signal attenuation.
Effect of Paclitaxel on the Distribution of ADC Values ofw
Tumors
(Twenty-four MCF7/S and MCF7/D40 tumors 6 treated
)and 6 controls of each type were analyzed by tumor vol-
ume and DWI for 7 days after commencement of Paclitaxel
CTx. As shown in Figure 3C and D, Paclitaxel arrested
growth in all MCF7/S tumors and had no effect on the
tumors from MCF7/D40 cells. After DWI examinations, the
data were fit on a pixel-by-pixel basis, and ADC mapsw
were generated for each tumor. These data were expressed
as a histogram of pixel incidence versus ADC . As thew
tumors were remarkably homogeneous within a group, the
ADC distribution was averaged for each group of tumors.
Figure 3A and B show histograms of ADC values inw
treated versus untreated tumors for both cell types 48 hours
after the start of Paclitaxel CTx. In MCF7/S tumors, the
ADC distribution in untreated tumors was 0.5;0.7=10y9w
m2/s, which was not notably different from the range ob-
served in tumors before treatment. However, in the treated
tumors, the ADC values were 0.7 to 1.5=10y9 m2/s. Inw
contrast, both treated and untreated MCF7/D40 tumors
exhibited ADC values similar to those observed in tumorsw
before treatment. Note also that these changes in the ADCw
were apparent 2 days after commencement of CTx. Al-
though there are observable differences in tumor volumes
( )between treated and controls by day 2 Figure 3C and D ,
these are not significant.
Discussion
Mechanism of ADC Changes
The mechanism underlying the change in ADC afterw
chemotherapy is unknown. However, data from other sys-
( )tems e.g., stroke indicate a direct relationship between
ADC and the extracellular volume fraction. If this mecha-w
nism also dominates the ADC values observed in tumors,w
then the higher values observed after CTx of the drug-sensi-
tive tumors would be consistent with a decrease in the
intracellular water after Paclitaxel-induced apoptosis. Pacli-
[ ]taxel is known to kill tumor cells via apoptosis 23–26 . A
hallmark of apoptosis is a reduction of cell volume via
blebbing. Benson et al. have shown that the decreases in
cell volume during apoptosis are biphasic, with an early
rapid phase that is reversible and a slower, irreversible
phase associated with chromosome condensation and DNA
[ ] ( )hydrolysis 27 . A recent study by Hakumaki et al. 1998
showed a 219% increase in the ADC of water in viralw
thymidine kinase–containing tumors induced to apoptosis
[ ]with ganciclovir 28 . In this system the relative fraction of
extracellular water grew from 87% to 94% in response to
CTx. The authors concluded that the measured nuclear
magnetic resonance parameters could describe the bio-
physical signatures for apoptotic cell death.
Mechanism of Paclitaxel CTx
Previous studies investigating the response of ADC tow
CTx used exclusively cytotoxic drugs. It would be of interest
to know if these changes also occur in modern cytostatic
drugs. Paclitaxel has both cytostatic and cytotoxic proper-
(ties. Clinically, Paclitaxel produces partial cytostasis ap-
) (proximately 30% maximum and apoptosis maximum apop-
) [ ]totic index of 3.3% to 29% in human breast tumors 23 . In
SKOV3 ovarian carcinoma cells treated with Paclitaxel, the
first cellular effect observed with continuous exposure to 50
( )ng/mL paclitaxel ID50 was mitotic arrest, followed by DNA
fragmentation, first detected at 24 hours and peaking at 48
hours. In this particular study, apoptosis was correlated with
[ ]an induction and activation of the c-Mos gene product. 24 .
Similar results were obtained in 3-dimensional histocultures
( )of ovarian tumors surgically removed from patients ns17 .
Paclitaxel was shown to produce a partial inhibition of DNA
precursor incorporation in about 40% of tumors and to
induce apoptosis in about 90% of tumors, with a maximum
[ ]apoptotic index of 15% 25 . Finally, in an extensive study of
6 differents cell lines, including bladder RT4, breast MCF7,
pharynx FaDu, ovarian SKOV3, and prostate PC3 and
DU145, Paclitaxel treatment for as brief a period as 3 hours
was sufficient to induce apoptosis, which occurred with a
lag time of about 24 hours. The intracellular and extracellu-
lar concentrations of the drug reached an equilibrium at
[ ]approximately 5 hours after the beginning of treatment 26 .
Thus, our results are consistent with the triggering of apop-
tosis by Paclitaxel in MCF7/S tumors, which induces a
larger extracellular space, shifting the ADC to higher val-w
ues.
ADC and MDRw
An important aspect of the current study is that Pacli-
taxel-induced effects were not observed in MCF7/D40 cells,
a P-gp-positive cell line. P-gp is an ATP-dependent drug
efflux pump that increases drug efflux when overexpressed.
P-gp expression renders cells cross-resistant to a wide
[ ]variety of drugs 29,30 . The defective accumulation of Pa-
clitaxel in P-gp overexpressing breast cancer cell lines was
14 [ ]demonstrated with C-Paclitaxel 7 . In another study
Mechetner et al. showed a strong correlation between the
degree of P-gp expression and in vitro resistance to Pacli-
[ ]taxel and doxorubicin in MCF-7/D40 cells 8 . Accordingly,
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we did not see any effect of Paclitaxel treatment on the
MCF7/D40 tumors in this study. It is noteworthy that Pacli-
taxel has also been shown to have antiangiogenic activity
[ ]31,32 . Presumably this could also have an effect on ADC
values as it would decrease the perfusion of the tumor to
induce hypoxia and subsequently trigger aptopotic cell death
as well. This does not seems to be the case, however,
because resistant and sensitive cells should have the same
vascular beds, and yet there were distinct responses of
ADC to CTx. The fact we do not see any Paclitaxel activityw
in MCF7/D40 tumors indicates that antiangiogenic effects
(are negligible at this stage of treatment 2 days after a 28
)mg/kg Paclitaxel intraperitoneal injection .
Conclusions
The results presented herein show that DWI can identify
CTx response and discriminate between sensitive and resis-
tant breast carcinoma tumors at an early stage of chemo-
therapy, i.e., before frank changes in tumor volume are
significant. Moreover, DWI can give a unique insight into the
spatial distribution of CTx effects within a tumor over the
course of treatment. This method can be easily adapted to
the clinic and has the potential to become a noninvasive
tool to evaluate the efficacy of CTx treatment in humans.
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